| The Editorial Policies and Process
The Journal of Immunotherapy and Precision Oncology (JIPO) adheres to the recommendations of the International Committee of Medical Journal Editors (ICMJE) and the Committee for Publication Ethics (COPE) guidelines to ensure best practices and ethical standards in the conduct and reporting of research and other material published in this journal.
A manuscript will be reviewed for possible publication with the understanding that it is being submitted to JIPO alone at that point in time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. The journal expects that authors would authorize one of them to correspond with the Journal for all matters related to the manuscript. All manuscripts received are duly acknowledged. On submission, editors review all submitted manuscripts initially for suitability for formal peer review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected without review. Manuscripts that are unlikely to be of interest to the JIPO readership are also liable to be rejected without peer review. Manuscripts that do not comply with the required format, as described herein, would be returned to the authors for technical correction before they undergo peer review.
Note - JIPO only accepts manuscripts written in English. A manuscript may be returned without peer review if the paper requires extensive editing for English language. In this case, the authors may seek a professional editing service or native speaker to make corrections prior to resubmitting.
Manuscripts that are considered for publication in JIPO are sent to two or more expert reviewers. During submission, the contributor is requested to provide names of two or three qualified reviewers who have had experience in the subject of the submitted manuscript, but this is not mandatory. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other’s identity. Every manuscript is also assigned to a member of the editorial team who, based on the comments from the reviewers, takes a final decision on the manuscript. The comments and suggestions (acceptance/ rejection/ amendments in manuscript) received from reviewers are conveyed to the corresponding author. If required, the author is requested to provide a point-by-point response to reviewers’ comments and submit a revised version of the manuscript. This process is repeated until the reviewers and editors are satisfied with the response and associated changes in the manuscript.
Manuscripts accepted for publication are copyedited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within 3 business days. The whole process of submission of the manuscript to final decision and sending and receiving proofs is completed online.
The journal publishes articles on its website immediately following proof corrections and follows a ‘continuous publication’ schedule. Articles are compiled for ‘print on demand’ quarterly issues.
How the Journal Handles Complaints and Appeals
The journal follows the recommendations of the ICMJE and COPE guidelines for handling complaints and appeals, which includes but is not limited to corrections, retractions, republications, and version control as well as reports of scientific misconduct and other expressions of concern.
| Clinical trial registry
Journal of Immunotherapy and Precision Oncology favors registration of clinical trials and is a signatory to the Statement on publishing clinical trials in Indian biomedical journals. Journal of Immunotherapy and Precision Oncology would publish clinical trials that have been registered with a clinical trial registry that allows free online access to public. Registration in the following trial registers is acceptable: http://www.clinicaltrials.gov/; http://www.ctri.in/; http://www.actr.org.au/; http://isrctn.org/; http://www.trialregister.nl/trialreg/index.asp; and http://www.umin.ac.jp/ctr. This is applicable to clinical trials that have begun enrollment of subjects in or after June 2008. Clinical trials that have commenced enrollment of subjects prior to June 2008 would be considered for publication in Journal of Immunotherapy and Precision Oncology only if they have been registered retrospectively with clinical trial registry that allows unhindered online access to public without charging any fees.
| Authorship Criteria
Authorship credit should be based only on substantial contributions to each of the three components mentioned below:
- Concept and design of study or acquisition of data or analysis and interpretation of data;
- Drafting the article or revising it critically for important intellectual content; and
- Final approval of the version to be published.
Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors.
The journal prescribes a maximum number of authors for manuscripts depending upon the type of manuscript, its scope and number of institutions involved (vide infra). Original research articles generally should not have more than 12 authors. The authors should provide a justification if the number of authors exceeds these limits.
| Contribution Details
Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided in following categories, as applicable: concept, design, definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review. One or more author should take responsibility for the integrity of the work as a whole from inception to published article and should be designated as the corresponding author.
| Conflicts of Interest / Competing Interests
All authors of must disclose any and all conflicts of interest they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript.
All sources of study-related funding must also be disclosed along with the grant number and role of funders in the study.
| Submission of Manuscripts
All manuscripts must be submitted online through the website, https://www.editorialmanager.com/jipo. First time users will have to register at this site. Registration is free but mandatory. Registered authors can keep track of their articles after logging into the site using their user name and password. Authors do not have to pay for submission, processing or publication of articles at this time (however, this may change in the future). If you experience any problems, please contact the editorial office by e-mail at editor [AT] jipoonline.org.
Manuscripts that are not submitted per the “Instructions to Authors” may be returned to the authors for technical correction prior to review. Generally, the manuscript should be submitted in the form of separate files as follows.
 Cover letter and title page:
The cover letter should be a doc, docx, or pdf file and include:
- A statement that the manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work, if that information is not provided in another form (see below); and
- The name, address, e-mail, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs.
- A full statement to the editor about all submissions and previous reports that might be regarded as redundant publication of the same or very similar work. Any such work should be referred to specifically, and referenced in the new paper. Copies of such material should be included with the submitted paper, to help the editor decide how to handle the matter.
The title page should provide:
- The type of manuscript (original article, review article, letter to editor, editorial, etc.), title of the manuscript, running title, names of all authors/contributors (with their highest academic degrees, designation and affiliations), and name(s) of department(s) and/or institution(s) to which the work should be credited. All information which can reveal your identity should be here.
- The total number of tables, figures, and words (excluding the references, tables, and abstract).
- Acknowledgements, if any. One or more statements should specify 1) contributions that need acknowledging but do not justify authorship, such as general support by a departmental chair; 2) acknowledgments of technical help; and 3) acknowledgments of financial and material support, which should specify the nature of the support.
- If the manuscript was presented as part at a meeting, include the organization, place, and date.
- Disclosures for each author including study-related funding and potential conflicts of interest (see statement above). If there are no disclosures, please state: The authors declare no financial support or conflicts of interest related to this manuscript.
- Registration number in case of a clinical trial and where it is registered (name of the registry and its URL)
- The name, address, e-mail, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs.
 Blinded Article File
The main document should be a .doc or .docx file and include:
- The main text of the article including the title, abstract, references, tables, and figure legends. Do not incorporate images in this file.
- The file must not contain any mention of the authors' names or initials or the institution at which the study was done or acknowledgements. Page headers/running title can include the title but not the authors' names. Manuscripts not in compliance with the Journal's blinding policy will be returned to the corresponding author.
- The pages should be numbered consecutively, beginning with the first page of the blinded article file.
 Figures / Images:
- Submit good quality color images as a jpeg, png, tiff, or gif file (not pdf).
- Resolution must be 300 dpi or higher
- Dimensions must be at least 5 inches wide
- Font size should be at least 11 or 12 point.
Sending a Revised Manuscript
The revised version of the manuscript should be submitted online in a manner similar to that used for submission of the manuscript for the first time. If there are changes in authorship (authors removed or added, change in order), this MUST be indicated on the cover letter and title page.
When submitting a revised manuscript, contributors are requested to include, the ‘referees’ remarks along with point to point clarification at the beginning in the revised file itself. In addition, they are expected to mark the changes as underlined or colored text in the article.
| Types of Manuscripts
Original articles include randomized controlled trials, intervention studies, studies of screening and diagnostic test, outcome studies, cost effectiveness analyses, case-control series, and surveys with high response rate.
These articles should adhere to the appropriate reporting guidelines.
For observational studies:
STROBE GUIDELINES - https://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_combined.pdf
The methodology section in the original research articles should strictly follow the STROBE reporting guidelines and ensure the reproducibility of the study.
For clinical trials:
CONSORT CHECKLIST - http://www.consort-statement.org/media/default/downloads/consort%202010%20checklist.pdf
The text of original articles amounting 3000-4000 words or less (excluding the tables, references, and abstract) should be divided into sections with the headings Abstract, Keywords, Introduction, Material and Methods, Results, Discussion, References, Tables and Figure legends. The abstract should be structured and not more than 250 words, followed by 3-5 keywords. ClinicalTrials.gov identifiers should be included at the end of the abstract.
These include systematic reviews, meta-analyses, and narrative / literature reviews. The allowed word count is up to 3000-4000 words excluding the tables, references, and abstract. The abstract should be unstructured, followed by 3-5 keywords.
Systematic Reviews, Meta-Analyses, Evidence-Based Recommendations
Please use the PRISMA reporting guidelines for systematic reviews: http://prisma-statement.org/documents/PRISMA%202009%20checklist.pdf
Systematic reviews, whether qualitative or quantitative (i.e., meta-analyses) should conform to the same reporting guidelines outlined above for Original Articles. Detailed search strategies, including the databases searched, date range, and inclusion/exclusion criteria should be included.
Narrative / Literature Reviews
It is expected that these articles would be written by individuals who have published substantial work or are considered experts in the field. The section titles would depend upon the topic reviewed. Authors submitting review articles should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the abstract.
These are short articles that communicate original research findings in the format of a letter. The length should be 500-1000 words, up to 10 references, and one table or figure. There should be no abstract or subheadings.
Please use the following reporting guidelines for case reports: https://www.care-statement.org/resources/checklist
Case reports should be unique, describing a great diagnostic or therapeutic challenge and providing a learning point for the readers within the subject of quality and safety of healthcare. Cases and short reports with clinical and health policy significance or implications will be given priority. These communications could be up to 1000 words (excluding abstract, tables, and references) and should have the following headings: Abstract (unstructured), Keywords, Introduction, Case Report, Discussion, References, Tables and Figure Legends, in that order. The manuscript could be supported with up to 10 references. Case Reports could be authored by no more than six authors.
Letter to the Editor
These should be short and decisive observations. They should preferably be related to articles previously published in JIPO or views expressed in the journal. They should not be preliminary observations that need a later paper for validation. The letter could have up to 500 words and 5 references.
Invited Editorials and Commentary
These are short opinion pieces that discuss a manuscript published in the Journal (Commentary) or topics selected by the editorial team (Editorial). They should have fewer than 1000 words total, no abstract, a minimal number of references (less than 10).
Guidelines and Consensus
Evidence-based guidelines will be considered for publication if they met the following criteria:
- Endorsed by non-profit professional organization or society
- Written by qualified multidisciplinary healthcare professionals (with appropriate disclosures for financial support and conflicting interests)
- Use sound methodology with clear categorization of evidence
- State clear recommendations with level of evidence and supporting references
Authors should read the standards for trustworthy guidelines: http://www.nationalacademies.org/hmd/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust/Standards.aspx
Like other submitted manuscripts, guidelines manuscripts will undergo the standard peer review process.
| Preparation of Manuscripts
Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journals" developed by the International Committee of Medical Journal Editors (October 2008) and the American Medical Association study guide. Before submitting a manuscript, contributors are requested to check for the latest instructions available.
Follow the reporting guidelines for specific study designs, as listed in the table below.
Reporting Guidelines for Specific Study Designs
||Type of Study
||Randomized controlled trials
||Studies of diagnostic accuracy
||Systematic reviews and meta-analyses
||http://www.consort- statement.org/Initiatives/MOOSE/moose.pdf statement.org/Initiatives/MOOSE/moose.pdf
||Observational studies in epidemiology
||Meta-analyses of observational studies in epidemiology
Summarize the most important aspects of the study in 250 words or less. A structured abstract (original articles only) should have the following headings: Introduction, methods, results, and conclusion. Unstructured abstracts should have no headings (reviews, case reports, letters, editorials, commentaries).
State the purpose and summarize the rationale for the study or observation. The introduction should clearly explain the main study question and/or hypothesis.
For original research articles, the methodology section should strictly follow the STROBE reporting guidelines and ensure the reproducibility of the study.
Be sure to include the following aspects:
When reporting studies on human beings, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at http://www.wma.net/e/policy/17-c_e.html).
For prospective studies involving human participants, authors are expected to mention approval of a regional/ national/ institutional or independent ethics committee or review board. The board name, board number, and date of approval should be reported. Written informed consent from study participants (adults and children 7 years of age and older) must be obtained and kept on file with the authors. The age beyond which consent would be required could vary as per regional and/ or national guidelines. Ensure confidentiality of subjects by desisting from mentioning participants’ names, initials or hospital numbers, especially in illustrative material.
When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on the care and use of laboratory animals was followed. Evidence for approval by a local Ethics Committee (for both human as well as animal studies) must be supplied by the authors on demand. Animal experimental procedures should be as humane as possible, and the details of anesthetics and analgesics used should be clearly stated. The ethical standards of experiments must be in accordance with the guidelines provided by the CPCSEA and World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Humans for studies involving experimental animals and human beings, respectively). The journal will not consider any paper which is ethically unacceptable. A statement on ethics committee permission and ethical practices must be included in all research articles under the ‘Materials and Methods’ section.
Selection and Description of Participants: Describe your selection of the observational or experimental participants (patients or laboratory animals, including controls) clearly, including eligibility and exclusion criteria and a description of the source population. Dates should be given in Month Day, Year format.
Technical information: Identify the methods, apparatus (give the manufacturer's name and location [city, state or country] in parentheses), and procedures in sufficient detail to allow other workers to reproduce the results. Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods, give reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration.
Reports of randomized clinical trials should present information on all major study elements, including the protocol, assignment of interventions (methods of randomization, concealment of allocation to treatment groups), and the method of masking (blinding), based on the CONSORT Statement (http://www.consort-statement.org).
Statistics: Whenever possible quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Authors should report losses to observation (such as, dropouts from a clinical trial). When data are summarized in the Results section, specify the statistical methods used to analyze them. Avoid non-technical uses of technical terms in statistics, such as 'random' (which implies a randomizing device), 'normal', 'significant', 'correlations', and 'sample'. Specify the computer software (with version number, manufacturer, and location) used. Use lowercase italics for p values (p = 0.048). Mean differences in continuous variables, proportions in categorical variables, and relative risks including odds ratios and hazard ratios should be accompanied by standard deviation or confidence intervals (i.e., 95% CI, 4–10).
- Present your results in a logical sequence in the text, tables, and illustrations, giving the main or most important findings first.
- Do not repeat in the text all the data in the tables or illustrations; emphasize or summarize only important observations.
- Extra or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text.
- When data are summarized in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated.
- Restrict tables and figures to those needed to explain the argument of the paper and to assess its support.
- Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables.
- Where scientifically appropriate, analyses of the data by variables such as age and sex should be included.
The discussion should summarize the following:
- Key findings (primary outcome measures, secondary outcome measures, results as they relate to a prior hypothesis or research question).
- Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation).
- Interpretation and implications in the context of the totality of evidence (refer to systematic reviews if available and explain what this study adds to the available evidence, the potential impact on patient care, health policy, and practice, the possible mechanisms).
- Controversies raised by this study.
- Future research directions (for this particular research collaboration, underlying mechanisms, healthcare quality and patient safety research).
Do not repeat in detail data or other material given in the Introduction or the Results section. In particular, authors should avoid making statements on economic benefits and costs unless their manuscript includes economic data and analyses. Avoid claiming priority and alluding to work that has not been completed. New hypotheses or research questions may be stated if needed; however, they should be clearly labeled as such.
This journal follows AMA Reference Style. For examples, please see below or follow this link: http://library.tu.edu/_resources/documents/AMACitationGuide.pdf
- References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order).
- Identify references in text, tables, and legends by Arabic numerals in superscript with square bracket after the punctuation marks. (This is an example.)
- References cited only in tables or figure legends should be numbered last.
- The titles of journals should be abbreviated according to the style used in Index Medicus.
- Avoid using abstracts and unpublished data as references.
- Avoid citing a "personal communication" unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text.
- Tables should be uploaded in an editable format (word doc or excel file, no images files or pdf files).
- Tables should be self-explanatory and should not duplicate textual material.
- Number tables using Arabic numerals consecutively in the order of their first citation in the text and supply a brief title for each.
- Place explanatory matter in footnotes, not in the heading.
- Explain in footnotes all non-standard abbreviations that are used in each table.
- Obtain permission for all fully borrowed, adapted, and modified tables and provide a credit line in the footnote.
- For footnotes use superscript numbers, letters, or symbols (*, †, ‡, §, ||,¶ , **, ††, ‡‡)
- Tables with their legends should be placed at the end of the text after the references. The tables along with their number should be cited at the relevant place in the text.
Figures (Graphs, Photographs, and Illustrations)
- Upload the images in jpeg, png, tiff, or gif format (not pdf) exactly how they should appear in the printed article. Figures are not edited by the production staff.
- Figures should be numbered consecutively according to the order in which they have been first cited in the text.
- Labels, numbers, and symbols should be clear and of uniform size (11 or 12 point font).
- Dimensions of the figure should be at least 5 inches wide.
- Resolution should be at least 300 dpi.
- Symbols, arrows, or letters used in photomicrographs should contrast with the background and should be marked neatly with transfer type or by tissue overlay and not by pen.
- Titles and detailed explanations belong in the legends for illustrations not on the illustrations themselves.
- When graphs, scatter-grams or histograms are submitted the numerical data on which they are based should also be supplied.
- The photographs and figures should be trimmed to remove all the unwanted areas.
- If photographs of individuals are used, their pictures must be accompanied by written permission to use the photograph.
- If a figure has been published elsewhere, acknowledge the original source and submit written permission from the copyright holder to reproduce the material. A credit line should appear in the legend for such figures.
- Legends for illustrations: Type or print out legends (maximum 40 words, excluding the credit line) for illustrations using double spacing, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one in the legend. Explain the internal scale (magnification) and identify the method of staining in photomicrographs.
- The Journal reserves the right to crop, rotate, reduce, or enlarge the photographs to an acceptable size.
| Copies of any permission(s)
It is the responsibility of authors/ contributors to obtain permissions for reproducing any copyrighted material. A copy of the permission obtained must accompany the manuscript. Copies of any and all published articles or other manuscripts in preparation or submitted elsewhere that are related to the manuscript must also accompany the manuscript.
|Protection of Patients' Rights to Privacy
Identifying information should not be published in written descriptions, photographs, sonograms, CT scans, etc., and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian, wherever applicable) gives written informed consent for publication. Authors should remove patients' names from figures unless they have obtained written informed consent from the patients. When informed consent has been obtained, it should be indicated in the article and copy of the consent should be attached with the covering letter.
|Reprints and proofs
Authors can purchase reprints, payment for which should be done at the time of submitting the proofs.
Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within 3 business days.
|Manuscript Submission, Processing, and Publication Charges
The journal does not charge the authors or authors’ institutions for the submission, processing, or publication of manuscripts at this time.
The entire contents of the Journal of Immunotherapy and Precision Oncology are protected under Indian and international copyrights. The Journal, however, grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.
Cover letter and title page
- Full names of all authors and their respective affiliations with city, state, and country
- Contact information (email and mailing address) for the corresponding author is given
- Previous publication / presentations of the same material are mentioned
- Source of funding mentioned for all authors; role of sponsor/funder in the study, if applicable
- Conflicts of interest disclosed for all authors
- Running title provided (not more than 50 characters)
- Abstract provided (structured abstract for original articles, unstructured abstracts for all other manuscripts excluding letters to the Editor)
- Registration number in case of a clinical trial and where it is registered (name of the registry and its URL)
- Keywords provided (three or more)
- Appropriate structure and headings are used
- Define each abbreviation at first mention in the title, abstract, keywords, and text unless it is a standard unit of measure.
- Numerals from 1 to 9 are spelled out unless followed by a unit of measure including time (i.e., 2 days, 5 mL)
- Use SI units for measurement, including capital L for liters.
- Minimize the use of bold and italics in text paragraphs. Species names and gene names should be in italics.
- Appropriate ethical statements included in the methods section.
- Manufacturer information (name and location) included for all equipment and software (with version number) in the methods section.
- All tables, figures, and references are cited in the text in numerical order.
- All tables and figure legends included at the end of the manuscript.
- In-text citations for reference should be after punctuation marks, superscript, inside square brackets.
- References are formatted according to the journal's instructions, punctuation marks checked.
- Always run spell check and grammar check.
- If it is a revised manuscript, send the article file with ‘Track Changes’.
Tables and figures
- Figures meet all requirements: at least 300 dpi, 5 inches wide, 11 or 12 point font size
- Patients' privacy maintained (if not, permission obtained)
- Permission and credit line provided for borrowed figures/tables
- All abbreviations and markers defined in footnotes
- Include appropriate units of measure.
- Define how values are presented (i.e., mean ± SD, n (%), etc.).
The contributor's form must be signed by all authors before the article can be published. It is not required until the article has been accepted. Please email the editorial office if you need a copy of the form.
Click here to download instructions
Click here to download copyright form
These ready to use templates are made to help the contributors write as per the requirements of the Journal.
Save the templates on your computer and use them with a word processor program.
Click open the file and save as the manuscript file.
In the program keep 'Document Map' and 'Comments' on from 'View' menu to navigate through the file.
Download Template for Original Articles/ABSTRACT Reports. (.DOT file)
Download Template for Case Reports. (.DOT file)
Download Template for Review Articles. (.DOT file)
Download Template for Letter to the Editor. (.DOT file)